BROACH Initiative

Broadening the Role of OB-GYNs in Assessing Cardiovascular Health

What is BROACH? 

Research has shown that OB-GYNs are the primary care providers for a large percentage of women, particularly young minority women. The Broadening the Role of OB-GYNs in Assessing Cardiovascular Health (BROACH) initiative aims to increase the number of women receiving cardiovascular risk factor screening at their annual OB-GYN visits by identifying the tools, resources and education needs identified from both the provider and patient perspective.

Our goal is to ensure that all women can identify their risks early, become empowered to lead more healthy lives, and help prevent heart disease from developing.

These materials were made possible by the Ivan Bowen Family Foundation as well as an unrestricted educational grant from Boston Scientific.

Provider Resource    Patient Resource

pregnant mother
Sunset

Make a Life-Changing Donation

Any gift, small or large, advances transformative research to save lives.

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.